An overview of the extra-lipid effects of rosuvastatin. (Q37156139)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18460672 AND SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

An overview of the extra-lipid effects of rosuvastatin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18460672 AND SRC:MED&resulttype=core&format=json

7 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18460672 AND SRC:MED&resulttype=core&format=json

7 January 2020

Moses Elisaf

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18460672 AND SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Haralampos J Milionis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18460672 AND SRC:MED&resulttype=core&format=json

7 January 2020

language of work or name

1 reference

6 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18460672 AND SRC:MED&resulttype=core&format=json

Journal of Cardiovascular Pharmacology and Therapeutics

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18460672 AND SRC:MED&resulttype=core&format=json

7 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18460672 AND SRC:MED&resulttype=core&format=json

7 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18460672 AND SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

157-174

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18460672 AND SRC:MED&resulttype=core&format=json

The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Do statins have an antiarrhythmic activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

A review of the lipid-related effects of fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Expanding options with a wider range of rosuvastatin doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Comparative pharmacology of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin treatment reverses impaired coronary artery vasodilation in fructose-fed, insulin-resistant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Statins prevent dextrose-induced endothelial barrier dysfunction, possibly through inhibition of superoxide formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: implication of the NAD(P)H oxidase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin treatment protects against nitrate-induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Antioxidant and antiplatelet effects of rosuvastatin in a hamster model of prediabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Highly active antiretroviral therapy attenuates re-endothelialization and alters neointima formation in the rat carotid artery after balloon injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Different migration of vascular smooth muscle cells from human coronary artery bypass vessels. Role of Rho/ROCK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Activation of NADPH oxidase during progression of cardiac hypertrophy to failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

RhoGDIgamma: a GDP-dissociation inhibitor for Rho proteins with preferential expression in brain and pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

3-HMG-Coenzyme A reductase inhibition and extracellular matrix gene expression in the pressure-overloaded rat heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

The protective effect of rosuvastatin on ischemic brain injury and its mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Intravenous rosuvastatin for acute stroke treatment: an animal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin reduces caspase-3 activity and up-regulates alpha-secretase in human neuroblastoma SH-SY5Y cells exposed to A beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Caspase activation in the limbic cortex of subjects with early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Alzheimer's disease: genes, proteins, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin-induced arrest in progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Dose-dependent effect of rosuvastatin treatment on urinary protein excretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

An overview of statin-associated proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin reduces rat intestinal ischemia-reperfusion injury associated with the preservation of endothelial nitric oxide synthase protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Rosuvastatin: a risk-benefit assessment for intensive lipid lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248408318628

21 January 2018

Identifiers

DOI

10.1177/1074248408318628

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18460672 AND SRC:MED&resulttype=core&format=json

7 January 2020

1 reference